Pomalidomide HCl WO 2018136700 A1 20180726

WO 2018136700 A1 20180726

Long-term treatment of spontaneously hypertensive rats with PD123319 and electrophysiological remodeling of left ventricular myocardium

MIC(90)s 0

and inhibition of cell proliferation

mitochondrial dysfunction and improves ventricular function in post-MI cardiomyopathy rats

Pomalidomide HCl WO 2018136700 A1 20180726Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8,